Asia Pacific Organoids Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Stomach, Intestine, Liver, Pancreas, Lung, Brain, Kidney, and Others), Application (Developmental Biology, Disease Pathology of Infectious Disease, Regenerat

Asia Pacific Organoids Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Stomach, Intestine, Liver, Pancreas, Lung, Brain, Kidney, and Others), Application (Developmental Biology, Disease Pathology of Infectious Disease, Regenerative Medicine, Drug Toxicity & Efficacy Testing, Drug Discovery & Personalized Medicine, and Others), and Source (Pluripotent Stem Cells and Organ-specific Adult Stem Cells)

The Asia Pacific organoids market is expected to grow from US$ 419.14 million in 2023 to US$ 1,207.66 million by 2028. It is estimated to record a CAGR of 23.6% from 2023 to 2028.

Combining Organoid with Organ-On-A-Chip to Fuel Asia Pacific Organoids Market During Forecast Period

Organoid and organ-on-a-chip, which serve as evolving and relevant pathological and human physiological in vitro models, have the potential to revolutionize the conventional paradigm of cancer research and produce real clinical benefits. The recent inclination in the collaborative application of organoids with organ-on-a-chip and 3D bioprinting enables the development of sophisticated cancer models to study underlying mechanisms of tumor-stroma interactions, multiorgan tumor metastasis, and cancer-microenvironment interactions. By incorporating multiple organoids into organ-on-a-chip, organoid-on-a-chip can inherit benefits of both organoid and organ-on-a-chip and provide a valuable tool to study multiorgan tumor metastases and cancer-microenvironment interactions.

In addition, technological advancements will facilitate various applications in biological and biomedical fields for disease modeling and clinical drug screening by combining organoids with organ-on-a-chip. Technological advancements have enabled the development of brain organoids-on-chip, liver organoids-on-chip, intestine organoids-on-chip, etc. Although organoid-on-a-chip is currently a developing field, there is potential for improvement. Hence, there is an increased requirement for cooperative efforts from interdisciplinary researchers to reach organoids' full utility in human biomedical studies. Thus, all these factors are expected to support the market growth in the coming years.

Asia Pacific Organoids Market Overview

The Asia Pacific organoids market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. The market in the region is likely to continue growing at the fastest rate during the forecast period owing to factors such as increasing incidences of cancer, growing demand for gene mutation and cancer research, government efforts to raise awareness related to human organoids, supportive regulations for the development and commercialization of advanced human organoids products, and increased funding for organoids research.

Asia Pacific Organoids Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Organoids Market Segmentation

The Asia Pacific organoids market is segmented on the basis of type, application, source, and country.

Based on type, the market is segmented into stomach, intestine, liver, pancreas, lung, brain, kidney, and others. The intestine segment registered the largest market share in 2023.

Based on application, the Asia Pacific organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held the largest market share in 2023.

Based on source, the Asia Pacific organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cells. The pluripotent stem cells segment held a larger market share in 2023.

Based on country, the Asia Pacific organoids market is segmented into Japan, China, India, South Korea, Australia, and the Rest of Asia Pacific. Japan dominated the market share in 2023.

Corning Inc; Merck kGaA; PeproTech, Inc; STEMCELL Technologies Inc; and Thermo Fisher Scientific Inc are the leading companies operating in the organoids market in Asia Pacific.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific Organoids Market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific Organoids Market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Organoids Market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution